Vimarsana
Biggest News Aggregation in the World

Villa Baca News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Villa Baca. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Villa Baca Today - Breaking & Trending Today

Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon® in IgA Nephropathy - Vimarsana News

Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon® in IgA Nephropathy

Published: March 13, 2023

/PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") today announced positive topline results from the global,...

Source: prnewswire.com
Related Topics:
United StatesUnited KingdomMarie GalayVilla BacaExchange CommissionKidney InternationalEuropean CommissionNefigard ToplineFull Prescribing InformationPrimary ImmunoglobulinNasdaq StockholmAmerican Depositary SharesNasdaq Global Select MarketPrivate Securities Litigation Reform ActCalliditas TherapeuticsLife ExpectancyPatients FromSoutheastern United States With IgaKidney Int RepNefigard Trial InvestigatorsWhy TargetTreat IgaIga NephropathyNationwide Population Based CohortHealth Care Amp Hospitals
Calliditas Therapeutics: Kidney International Publishes Results from NefIgArd Phase 3 Trial Evaluating TARPEYO (budesonide) in IgA Nephropathy - Vimarsana News

Calliditas Therapeutics: Kidney International Publishes Results from NefIgArd Phase 3 Trial Evaluating TARPEYO (budesonide) in IgA Nephropathy

Published: October 19, 2022

STOCKHOLM, Oct. 19, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced Kidney International has published the successful

Source: finanznachrichten.de
Related Topics:
Marie GalayVilla BacaExchange CommissionKidney International Press ReleaseKidney InternationalLifesci CommunicationsNasdaq StockholmNefigard PartNefigard PhaseChief Executive OfficerFull Prescribing InformationPrimary ImmunoglobulinNasdaq Global Select MarketPrivate Securities Litigation Reform ActInvestor Relations ManagerCalliditas Media ContactCalliditas TherapeuticsLife ExpectancyPatients FromSoutheastern United States With IgaKidney Int RepWhy TargetTreat IgaIga NephropathyNationwide Population Based Cohort
Kidney International Publishes Results from NefIgArd Phase 3 Trial Evaluating TARPEYO® (budesonide) in IgA Nephropathy - Vimarsana News

Kidney International Publishes Results from NefIgArd Phase 3 Trial Evaluating TARPEYO® (budesonide) in IgA Nephropathy

Published: October 19, 2022

/PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced Kidney International has published the...

Source: prnewswire.com
Related Topics:
Marie GalayVilla BacaExchange CommissionKidney International Press ReleaseKidney InternationalLifesci CommunicationsNasdaq StockholmNefigard PartNefigard PhaseChief Executive OfficerFull Prescribing InformationPrimary ImmunoglobulinNasdaq Global Select MarketPrivate Securities Litigation Reform ActInvestor Relations ManagerCalliditas Media ContactCalliditas TherapeuticsLife ExpectancyPatients FromSoutheastern United States With IgaKidney Int RepWhy TargetTreat IgaIga NephropathyNationwide Population Based Cohort
Calliditas Therapeutics Announces Commercial Availability and Initial Sales of TARPEYO - Vimarsana News

Calliditas Therapeutics Announces Commercial Availability and Initial Sales of TARPEYO

Published: January 28, 2022

STOCKHOLM, Jan. 28, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced the commercial availability and initial sales of TARPEYO

Source: finanznachrichten.de
Related Topics:
United StatesAndrew UdellMarie GalayVilla BacaExchange CommissionEuropean Medicines AgencyNasdaq StockholmPresident NorthIga NephropathyNasdaq Global Select MarketFull Prescribing InformationPrivate Securities Litigation Reform ActLife ExpectancyPatients FromSoutheastern United States With IgaKidney Int Rep
Calliditas Therapeutics Announces Commercial Availability and Initial Sales of TARPEYO™ - Vimarsana News

Calliditas Therapeutics Announces Commercial Availability and Initial Sales of TARPEYO™

Published: January 28, 2022

/PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced the commercial availability and initial...

Source: prnewswire.com
Related Topics:
United StatesAndrew UdellMarie GalayVilla BacaExchange CommissionEuropean Medicines AgencyNasdaq StockholmPresident NorthIga NephropathyNasdaq Global Select MarketFull Prescribing InformationPrivate Securities Litigation Reform ActLife ExpectancyPatients FromSoutheastern United States With IgaKidney Int RepCalliditas Therapeutics